NaviGate Cardiac Structures Inc. (“NCSI”) reports “excellent valvular function” at 1-year follow-up of first patient to receive GATE™ tricuspid valved stent via transjugular access


May 29, 2018   •  Press Release

LAKE FOREST, Calif.--(BUSINESS WIRE)--NaviGate Cardiac Structures Inc. (“NCSI”) announced today that the first patient to receive its replacement tricuspid valved stent via transjugular access has reached one-year post-procedure with excellent valvular function. This patient, along with 15 others treated to date under compassionate use protocols for severe tricuspid regurgitation, have received NCSI’s GATE™ tricuspid valved stent designed to lead to restored valvular function and…

Continue Reading

Quebec University in Laval, Canada. This is the first tricuspid valve replacement in Canada.


Feb 12, 2018   •  Press Release

Communiqué de presse PREMIÈRE MÉDICALE CANADIENNE : UN 10E CAS DE REMPLACEMENT TRICUSPIDE PERCUTANÉ AU MONDE RÉALISÉ À L’INSTITUT Québec, 8 février 2018 – L’Institut universitaire de cardiologie et de pneumologie de Québec– Université Laval (l’Institut) a récemment procédé avec succès à un premier cas deremplacement tricuspide percutané. Jusqu’à maintenant, seulement 10 patients dans le mondeont subi ce type de remplacement percutané. La procédure a été…

Continue Reading

NaviGate Cardiac Structures, Inc. Reports “Exceptional” Six-Week Results for Two Implantations of Its GATE™ Atrioventricular Valved Stent (AVS)


Nov 29, 2017   •  Business Wire

LAKE FOREST, Calif. — NaviGate Cardiac Structures Inc. ("NCSI") announced today "exceptional results" for implantation of its GATE™ catheter-guided tricuspid atrioventricular valved stent (AVS) at six-week follow-up in two nonagenarian patients presenting with severe tricuspid valve insufficiency. Implantations of the GATE™ AVS were performed at New York-Presbyterian/Columbia University…

View Press Release

FOR IMMEDIATE RELEASE - Contact: Ronald Trahan, APR, Ronald Trahan Associates, 1 (508) 359-4005, x108

NaviGate Cardiac Structures, Inc. (“NCSI”) reports world’s first successful transcatheter implantation of 52-mm tricuspid valve into a transplanted-heart patient


Aug 30, 2017   •  Business Wire

LAKE FOREST, Calif., Aug. 30, 2017 - NaviGate Cardiac Structures Inc. ("NCSI") announced today that its GATE™ catheter-guided tricuspid atrioventricular valved stent (A VS) was implanted through the jugular vein six weeks ago into a patient's transplanted heart that was failing due to severe tricuspid valve insufficiency. The successful implantation of the GATE™ A VS at the Policlinico of the…

View Press Release

FOR IMMEDIATE RELEASE - Contact: Ronald Trahan, APR, Ronald Trahan Associates, 1 (508) 359-4005, x108

NaviGate Cardiac Structures, Inc. (“NCSI”) reports first heterotopic transcatheter GATE™ tricuspid valved stent successful implantation


Apr 26, 2017   •  Press Release

LAKE FOREST, Calif., Apr, 26, 2017 - NaviGate Cardiac Structures Inc. (“NCSI”) announced today that the GATE™ catheter-guided tricuspid atrioventricular valved stent (AVS) was implanted through the jugular vein one week ago in a patient suffering from severe tricuspid regurgitation stemming from two failed tricuspid annuloplasty rings that were unable to maintain the patient’s valve competence. The patient, a 78-year-old man with a long history of cardiac conditions, has undergone…

Continue Reading

NaviGate Cardiac Structures Inc. (“NCSI”) reports world’s first transcatheter tricuspid valved stent is successfully implanted


Dec 30, 2016   •  Business Wire

LAKE FOREST, Calif., Dec. 30, 2016 — NaviGate Cardiac Structures Inc. ("NCSI") announced today that a novel valved stent that can capture the enlarged annulus in patients suffering from functional tricuspid regurgitation (FTR) was implanted in a patient presenting with massive incompetence of the tricuspid valve. The patient, a 64-year-old female with an extensive history of severe tricuspid…

View Press Release

FOR IMMEDIATE RELEASE - Contact: Ronald Trahan, APR, Ronald Trahan Associates, 1 (508) 359-4005, x108

NaviGate Cardiac Structures, Inc., presents data of studies on the Gate™ valved stent for correction of Functional Tricuspid Regurgitation at Paris PCR2016.


Jun 23, 2016   •  Announcement

Jose L Navia, M.D., from Cleveland Clinic presented the summary of animal studies of the Gate™valved stent for catheter-guided orthotopic implantation procedure for the correction of Functional Tricuspid Regurgitation (FTR).  Functional tricuspid regurgitation occurs yearly in close to 2 million patients in the USA, as reported by Stuge & Liddicoat previously.  These patients are for a large part categorized as inoperable by the STS (Society of Thoracic Surgery) guidelines, that is, at…

Continue Reading

First NAVI™ patient at 8 months shows excellent mitral valve function and has returned to work


Jun 23, 2016   •  Announcement

NaviGate Cardiac Structures, Inc. has received approval from Krakow, Poland, Ethics Committee  to implant the Navi™ Valved Stent for correction of severe Functional Mitral Regurgitation (FMR). NCSI has received approval from the regional Ethics Committee to implant the Navi™valved stent for the correction of severe mitral regurgitation (MR) in patients considered inoperable by standard cardiac surgery that requires open chest, open and arrested heart and cardiopulmonary bypass because of…

Continue Reading

NaviGate Cardiac Structures Inc. (“NCSI”) reports first patient treated for mitral regurgitation (“MR”)


Nov 23, 2015   •  Business Wire

LAKE FOREST, Calif. – NaviGate Cardiac Structures Inc. (NCSI) announced today that a First-In-Human implant of it's catheter-guided, mitral-valved stent into a beating heart was performed successfully in a 53-year-old male patient presenting with severe 4+* MR. The interventional team was led by Dr. Cristián Baeza Prieto at San Borja Arriarán Hospital in Santiago, Chile, on October 26, 2015.…

View Press Release

FOR IMMEDIATE RELEASE - Contact: Ronald Trahan, APR, Ronald Trahan Associates, 1 (508) 359-4005, x108